EOIB for Laparoscopic Sleeve Gastrectomy
Launched by ONDOKUZ MAYIS UNIVERSITY · Jul 28, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help manage pain after a type of weight-loss surgery called laparoscopic sleeve gastrectomy, which is often done for people with obesity. The study will test a pain relief technique called the external oblique intercostal block (EOIB). This method aims to reduce pain and the need for opioid pain medicines during the first 24 hours after surgery, while also trying to lower common side effects like nausea and vomiting. The goal is to make recovery more comfortable and possibly shorten the hospital stay.
Adults between 18 and 65 years old who are having this surgery might be eligible to join the study, as long as they don’t have certain health issues like long-term opioid use, chronic pain, severe heart, liver, or kidney problems, or allergies to pain medications. Participants will receive the EOIB treatment during surgery and will be monitored for pain levels and medication use afterward. It’s important to note that the study hasn’t started enrolling patients yet, and anyone interested would need to give informed consent and meet all the health criteria. This trial could offer a promising new way to improve pain control after weight-loss surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-65 years
- Exclusion Criteria:
- • Patients who did not sign the informed consent form and did not wish to participate in the study Patients with a history of opioid use lasting longer than four weeks Patients with chronic pain Patients with a history of allergy or hypersensitivity to local anesthetics or opioids Presence of severe cardiac, hepatic, or renal disease Patients with alcohol or drug addiction Conditions contraindicating the application of regional anesthesia Patients with severe psychiatric disorders such as psychosis or dementia that limit cooperation Block failure identified by dermatomal examination after the procedure Patients with a STOP-BANG score \> 5
About Ondokuz Mayıs University
Ondokuz Mayıs University is a prestigious academic institution located in Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its cutting-edge facilities and a multidisciplinary team of experts to conduct innovative studies that aim to enhance patient care and contribute to scientific knowledge. With a focus on ethical standards and rigorous methodologies, Ondokuz Mayıs University is dedicated to fostering collaborations that drive breakthroughs in healthcare, ultimately improving treatment outcomes and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported